<DOC>
	<DOC>NCT00846196</DOC>
	<brief_summary>Randomized, double-blind, 2-treatment, 2-period, 2-sequence, crossover study, The study will consist of a screening visit, study center admission (preceding Treatment Periods 1 and 2), 2 treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1 and 2), and exit procedures.</brief_summary>
	<brief_title>A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>male or female, 18 to 65 years of age if female, nonlactating and either surgically sterile or postmenopausal body mass index less than or equal to 32 kg/m2 at screening no use of a bisphosphonate within 1 month no history of GI disease no use of any medications within 714 days prior to scheduled dosing day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>